P21

P21 Anti-Aging & Longevity Profile

P21 serves as a foundational element within life extension research, specifically designed to interdict genetic degradation, preserve mitochondrial function, and aggressively target senescent cell buildup.

Pharmacological Profile

Parameter	Value
Molecular Formula	C107H179N35O35
Molecular Mass	2499.7 g/mol
Assay Purity	>98.0%
Appearance	Lyophilized solid

Figure 1: P21 Cellular Transduction Representation

Genomic Mechanism of Action

Observations of the exact signaling cascade leading to its theoretical longevity effects:

1. Acts as a powerful neurogenic and neuroprotective analogue of Ciliary Neurotrophic Factor (CNTF).
2. Specifically bypasses the unwanted weight loss side-effects of full-length CNTF.
3. Binds to neurogenesis receptors, heavily upregulating Brain-Derived Neurotrophic Factor (BDNF).
4. Promotes the rapid creation and survival of new neurons in the dentate gyrus.
5. Increases synaptic plasticity and dendrite formation in mature brains.

Figure 2: Empirical Longevity Outcomes & Age Reversal Metrics

Primary Research Vectors

• Study 1: Under intense investigation for reversing Alzheimer's pathology and plaque formation.
• Study 2: Significantly enhances object recognition and spatial memory in impaired models.
• Study 3: Offers one of the highest known neurotrophic boosts without systemic toxicity.

Nerve Growth Factor Mimetic Peptide

P21 (also known as P021) is a modified dipeptide derived from the ciliary neurotrophic factor (CNTF) active region, engineered to be lipophilic enough to cross the blood-brain barrier. It was designed at the New York State Institute for Basic Research in Developmental Disabilities as a small-molecule neurotrophic compound that bypasses the pharmacological limitations of full-length neurotrophins (which are too large to penetrate the BBB and have short systemic half-lives). P21 enhances neurogenesis and reduces neurodegeneration through a dual mechanism.

1. P21 inhibits leukemia inhibitory factor (LIF) signaling, which tonically suppresses neuronal stem cell proliferation in the adult hippocampal subgranular zone.
2. By relieving this LIF-mediated brake, P21 promotes proliferation and differentiation of neural progenitor cells in the dentate gyrus.
3. Simultaneously, P21 increases BDNF (brain-derived neurotrophic factor) expression in the hippocampus and cortex via CREB phosphorylation.
4. Elevated BDNF activates TrkB receptors on existing neurons, enhancing long-term potentiation (LTP) and synaptic plasticity—the cellular basis of learning and memory.
5. P21 also reduces the phosphorylation of tau protein at AD-relevant epitopes (Ser262, Ser396), potentially slowing neurofibrillary tangle formation.

Alzheimer’s Disease & Cognitive Research

• AD Mouse Models: In 3xTg-AD mice, chronic P21 administration rescued spatial memory deficits (Morris water maze), increased hippocampal neurogenesis by 50%, and reduced tau hyperphosphorylation.
• Aged Wild-Type Mice: Even in normal aging (non-transgenic), P21 improved cognitive performance and increased dendritic spine density in CA1 hippocampal neurons.
• Oral Bioavailability: A key advantage of P21 over full-length neurotrophins is its oral bioavailability. Studies have demonstrated efficacy via gavage administration, opening the door to chronic oral dosing.
• Safety: Chronic administration (up to 12 months in rodent studies) showed no tumor promotion, organ toxicity, or behavioral abnormalities, distinguishing it from direct neurotrophin administration.
• Dual Action: The combination of enhanced neurogenesis (new neurons) and neuroprotection (reduced tau pathology) makes P21 unique among neurotrophic compounds in addressing both regenerative and degenerative aspects of cognitive decline.